Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 74Tumor-Agnostic 8Breast 6Thoracic 5Gastrointestinal 5CNS 4Head & Neck 3Sarcoma 2Other solid neoplasm 2Gynecologic 2Plasma cell 1Other hematologic neoplasm 1Myeloid 1Lymphoid 1Endocrine 1Classical hematology 1

Conditions

Ovarian Neoplasms 2Recurrence 1

Interventions

Paclitaxel 575Carboplatin 520Cisplatin 347Bevacizumab 252pembrolizumab 226Gemcitabine 157Topotecan 128liposomal doxorubicin 127Cyclophosphamide 126olaparib 120Taxes 113Radiotherapy 110Docetaxel 94Brachytherapy 89Doxorubicin 84Drug Therapy 80niraparib 75Nivolumab 71Magnetic Resonance Spectroscopy 71Specimen Handling 65fludarabine 56Biopsy 55Hyperthermic Intraperitoneal Chemotherapy 53Filgrastim 52Letrozole 50Oxaliplatin 48durvalumab 47Immunoglobulin G 47atezolizumab 46Platinum 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × cabazitaxel × Gynecologic × Clear all
NCT02560337 2020-10-08

CaTo-ROC

Vejle Hospital

Phase 2 Completed
26 enrolled
Gynecologic

Ovarian Neoplasms, Recurrence

NCT01747239 2014-12-04

Cabazitaxel in Platinum Refractory Ovarian Cancer

Vejle Hospital

Phase 2 Terminated
4 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡